19-Hydroxy-pgb2 | 67392-20-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 19-Hydroxy-pgb2
• 英文别名: (Z)-7-[2-[(E,3S)-3,7-dihydroxyoct-1-enyl]-5-oxocyclopenten-1-yl]hept-5-enoic acid
• CAS: 67392-20-5
• 化学式: C₂₀H₃₀O₅
• 分子量: 350.4
• InChiKey: PPYRMVKHPFIXEU-BAKUXOMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
  申请人：——

  公开号：US20020013304A1

  公开（公告）日：2002-01-31

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括给药含有有效量雄性激素的药物制剂，其中给药是按需给药，而不是长期药物治疗。局部给药可通过给药到个人的阴道、外阴部或尿道来实现，但对于那些口服活性的雄性激素制剂来说，口服给药是首选。此外，还提供了用于实施该方法的制剂和试剂盒。
• Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
  申请人：——

  公开号：US20020099003A1

  公开（公告）日：2002-07-25

  Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal polypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.

  本研究提供了治疗女性性功能障碍的方法。将含有选自血管活性肠多肽（VIP）和 VIP 激动剂的血管活性剂的药物组合物施用到接受治疗者的阴道和/或外阴区域。这些制剂还可用于改善阴道肌肉张力和组织健康，提高阴道润滑度，减少过量胶原蛋白沉积。此外，还提供了药物制剂和试剂盒。
• As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
  申请人：——

  公开号：US20030022875A1

  公开（公告）日：2003-01-30

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves oral administration of a dosage form containing an effective amount of an orally active androgenic agent, and is on an as-needed basis rather than involving chronic pharmacotherapy. Oral pharmaceutical compositions, dosage forms and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括口服含有有效量口服活性雄性激素的剂型，并且是按需给药，而不是长期药物治疗。此外，还提供了用于实施该方法的口服药物组合物、剂型和试剂盒。
• Treatment of dyspareunia with topically administered nitroglycerin formulations
  申请人：——

  公开号：US20040044080A1

  公开（公告）日：2004-03-04

  Methods and formulations for treating dyspareunia are provided. A pharmaceutical composition formulated so as to contain a therapeutically effective amount of nitroglycerin is administered to the vagina or vulvar area of the individual undergoing treatment. Preferred formulations are immediate release formulations in which at least 80% of the nitroglycerin in the formulation is released therefrom within 4 hours following administration. The formulations may contain one or more additional active agents, e.g., agents that are also useful to treat dyspareunia and/or potentiate the action of nitroglycerin. Such additional agents include vasoactive agents such as prostaglandins, phosphodiesterase inhibitors, androgens such as testosterone, estrogens such as estradiol, and selective modulators of estrogen and androgen receptors. A kit for a patient to use in the self-administration of the formulation is also provided.

  本研究提供了治疗性交困难的方法和制剂。将配制成含有治疗有效量硝化甘油的药物组合物施用到接受治疗者的阴道或外阴部位。首选的制剂是速释制剂，其中制剂中至少 80% 的硝酸甘油在给药后 4 小时内从制剂中释放出来。制剂可含有一种或多种额外的活性剂，例如，也可用于治疗性交困难和/或增强硝酸甘油作用的制剂。此类附加制剂包括血管活性剂，如前列腺素、磷酸二酯酶抑制剂、雄激素，如睾酮、雌激素，如雌二醇，以及雌激素和雄激素受体的选择性调节剂。此外，还提供了一种供患者用于自行服用制剂的试剂盒。
• Treatment of female sexual dysfunction with phosphodiesterase inhibitors
  申请人：——

  公开号：US20040014761A1

  公开（公告）日：2004-01-22

  A topical pharmaceutical composition is provided for the treatment of female sexual dysfunction, wherein the composition is formulated so as to contain a therapeutically effective amount of a phosphodiesterase inhibitor and a pharmaceutically acceptable carrier for topical administration. The phosphodiesterase inhibitor is generally selected from Type III, Type IV, Type V, and nonspecific phosphodiesterase inhibitors.

  提供了一种用于治疗女性性功能障碍的外用药物组合物，其中该组合物经配制后含有治疗有效量的磷酸二酯酶抑制剂和用于局部给药的药学上可接受的载体。磷酸二酯酶抑制剂一般选自 III 型、IV 型、V 型和非特异性磷酸二酯酶抑制剂。